Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets

References

• Mei L, Smith SC, Faber AC, et al. Gastrointestinal stromal tumors: the GIST of precision medicine. Trends Cancer. 2018;4(1):74–91. doi:10.1016/j.trecan.2017.11.00629413424
   PubMed Web of Science ®Google Scholar
• Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. nat rev cancer. 2011;11(12):865–878. doi:10.1038/nrc314322089421
   PubMed Web of Science ®Google Scholar
• Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol. 2014;6(3):115–127. doi:10.1177/175883401452249124790651
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (London, England). 2006;368(9544):1329–1338. doi:10.1016/S0140-6736(06)69446-4
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and Safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302. doi:10.1016/S0140-6736(12)61857-123177515
   PubMed Web of Science ®Google Scholar
• Hemming ML, Heinrich MC, Bauer S, George S. Translational insights into gastrointestinal stromal tumor and current clinical advances. Ann Oncol Off J Eur Soc Med Oncol. 2018. doi:10.1093/annonc/mdy309
   Google Scholar
• Liegl B, Kepten I, Le C, et al. Heterogeneity of Kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216(1):64–74. doi:10.1002/path.238218623623
   PubMed Web of Science ®Google Scholar
• Yoo C, Ryu M-H, Jo J, Park I, Ryoo B-Y, Kang Y-K. Efficacy of imatinib in patients with platelet-derived growth factor receptor alpha–mutated gastrointestinal stromal tumors. Cancer Res Treat. 2016;48(2):546–552. doi:10.4143/crt.2015.01526130666
   PubMed Web of Science ®Google Scholar
• Cassier PA, Fumagalli E, Rutkowski P, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012;18(16):4458–4464. doi:10.1158/1078-0432.CCR-11-302522718859
   PubMed Web of Science ®Google Scholar
• Van Looy T, Wozniak A, Floris G, et al. Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy. Clin Cancer Res. 2014;20(23):6071–6082. doi:10.1158/1078-0432.CCR-14-182325316817
   PubMed Web of Science ®Google Scholar
• Fritsch C, Huang A, Chatenay-Rivauday C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014;13(5):1117–1129. doi:10.1158/1535-7163.MCT-13-086524608574
   PubMed Web of Science ®Google Scholar
• Serrano C, Wang Y, Mariño-Enríquez A, et al. KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation. J Clin Oncol. 2015;33(22):e93–6. doi:10.1200/JCO.2013.48.748824687822
   PubMed Web of Science ®Google Scholar
• Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene. 2007;26(54):7560–7568. doi:10.1038/sj.onc.121055817546049
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501. doi:10.1038/nrc83912094235
   PubMed Web of Science ®Google Scholar
• Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/MTOR pathway. Curr Oncol Rep. 2013;15(4):386–395. doi:10.1007/s11912-013-0316-623605780
   PubMed Web of Science ®Google Scholar
• Ríos-Moreno MJ, Jaramillo S, Díaz-Delgado M, et al. Differential activation of MAPK and PI3K/AKT/MTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res. 2011;31(9):3019–3025.21868553
   PubMed Web of Science ®Google Scholar
• Ulukaya E, Colakogullari M, Wood EJ. Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay. Chemotherapy. 2004;50(1):43–50. doi:10.1159/00007728515084806
   PubMed Web of Science ®Google Scholar
• Kumar P, Henikoff S, Ng PC. predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073–1081. doi:10.1038/nprot.2009.8619561590
   PubMed Web of Science ®Google Scholar
• Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–249. doi:10.1038/nmeth0410-24820354512
   PubMed Web of Science ®Google Scholar
• Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361–362. doi:10.1038/nmeth.289024681721
   PubMed Web of Science ®Google Scholar
• Barault L, Amatu A, Siravegna G, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. 2017. doi:10.1136/gutjnl-2016-313372 gutjnl-2016-313372.
   PubMed Web of Science ®Google Scholar
• Moran S, Arribas C, Esteller M. Validation of a DNA methylation microarray for 850,000 cpg sites of the human genome enriched in enhancer sequences. Epigenomics. 2016;8(3):389–399. doi:10.2217/epi.15.11426673039
   PubMed Web of Science ®Google Scholar
• Omarini C, Filieri ME, Bettelli S, et al. Mutational profile of metastatic breast cancer tissue in patients treated with exemestane plus everolimus. Biomed Res Int. 2018;2018:3756981. doi:10.1155/2018/375698130140695
   PubMed Web of Science ®Google Scholar
• Tessitore A, Bruera G, Mastroiaco V, et al. KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. Hum Pathol. 2018;74:178–182. doi:10.1016/j.humpath.2018.01.02129409955
   PubMed Web of Science ®Google Scholar
• Lai K, Killingsworth MC, Lee CS. Gene of the Month: PIK3CA. J Clin Pathol. 2015;68(4):253–257. doi:10.1136/jclinpath-2015-20288525688137
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. doi:10.1126/science.109650215016963
   PubMed Web of Science ®Google Scholar
• Vlachos IS, Zagganas K, Paraskevopoulou MD, et al. DIANA-MiRPath v3.0: deciphering MicroRNA function with experimental support. Nucleic Acids Res. 2015;43(W1):W460–W466. doi:10.1093/nar/gkv40325977294
   PubMed Web of Science ®Google Scholar
• Chou C-H, Shrestha S, Yang C-D, et al. MiRTarBase update 2018: a resource for experimentally validated MicroRNA-target interactions. Nucleic Acids Res. 2018;46(D1):D296–D302. doi:10.1093/nar/gkx106729126174
   PubMed Web of Science ®Google Scholar
• Mühlenberg T, Zhang Y, Wagner AJ, et al. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res. 2009;69(17):6941–6950. doi:10.1158/0008-5472.CAN-08-400419706776
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352–5359. doi:10.1200/JCO.2007.15.746118955458
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12(6):1743–1749. doi:10.1158/1078-0432.CCR-05-121116551858
   PubMed Web of Science ®Google Scholar
• Beretta GL, Cassinelli G, Pennati M, Zuco V, Gatti L. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem. 2017;142:271–289. doi:10.1016/j.ejmech.2017.07.06228851502
   PubMed Web of Science ®Google Scholar
• Choi YH, Yu A-M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des. 2014;20(5):793–807. doi:10.2174/13816128200514021416521223688078
   PubMed Web of Science ®Google Scholar
• Klukovits A, Krajcsi P. Mechanisms and therapeutic potential of inhibiting drug efflux transporters. Expert Opin Drug Metab Toxicol. 2015;11(6):907–920. doi:10.1517/17425255.2015.102891725802976
   PubMed Web of Science ®Google Scholar
• Raveh E, Matouk IJ, Gilon M, Hochberg A. The H19 long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory. Mol Cancer. 2015;14(1):184. doi:10.1186/s12943-015-0458-226536864
   PubMedGoogle Scholar
• Huarte M. The emerging role of LncRNAs in cancer. Nat Med. 2015;21(11):1253–1261. doi:10.1038/nm.398126540387
   PubMed Web of Science ®Google Scholar
• Yang Q, Wang X, Tang C, Chen X, He J. H19 promotes the migration and invasion of colon cancer by sponging MiR-138 to upregulate the expression of HMGA1. Int J Oncol. 2017;50(5):1801–1809. doi:10.3892/ijo.2017.394128358427
   PubMed Web of Science ®Google Scholar
• Li H, Yu B, Li J, et al. Overexpression of LncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5(8):2318–2329. doi:10.18632/oncotarget.191324810858
   PubMedGoogle Scholar
• Xue L, Wang Y, Yue S, Zhang J. The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis. Neurol Sci. 2017;38(1):67–73. doi:10.1007/s10072-016-2710-y
   PubMed Web of Science ®Google Scholar
• Chi P, Chen Y, Zhang L, et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010;467(7317):849–853. doi:10.1038/nature0940920927104
   PubMed Web of Science ®Google Scholar
• Yang W, Redpath R, Zhang C, Ning N. Long non‑coding RNA H19 promotes the migration and invasion of colon cancer cells via MAPK signaling pathway. Oncol Lett. 2018;16(3):3365–3372. doi:10.3892/ol.2018.905230127936
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Peng W, Calvo E. Rational approaches for combination therapy strategies targeting the MAP kinase pathway in solid tumors. Mol Cancer Ther. 2018;17(1):3–16. doi:10.1158/1535-7163.MCT-17-034929295962
   PubMed Web of Science ®Google Scholar
• Aksamitiene E, Kiyatkin A, Kholodenko B.N. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans. 2012;40(5):139–146. doi:10.1042/BST2011060922260680
   PubMedGoogle Scholar
• Alonso N, Diaz Nebreda A, Monczor F, et al. PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells. Biochim Biophys Acta. 2016;1860(9):1998–2007. doi:10.1016/j.bbagen.2016.06.01627316323
   PubMed Web of Science ®Google Scholar
• Serra V, Scaltriti M, Prudkin L, et al. PI3K Inhibition Results in Enhanced HER Signaling and Acquired ERK Dependency in HER2-Overexpressing Breast Cancer. Oncogene. 2011;30(22):2547–2557. doi:10.1038/onc.2010.62621278786
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14(12):1351–1356. doi:10.1038/nm.189019029981
   PubMed Web of Science ®Google Scholar
• Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer. 2014;14(11):747–753. doi:10.1038/nrc381925253389
   PubMed Web of Science ®Google Scholar
• Knoechel B, Roderick JE, Williamson KE, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46(4):364–370. doi:10.1038/ng.291324584072
   PubMed Web of Science ®Google Scholar
• Salgia R, Kulkarni P. The genetic/non-genetic duality of drug ‘resistance’ in cancer. Trends Cancer. 2018;4(2):110–118. doi:10.1016/j.trecan.2018.01.00129458961
   PubMed Web of Science ®Google Scholar
• Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics. 2015;7:127. doi:10.1186/s13148-015-0157-226692909
   PubMed Web of Science ®Google Scholar
• Bauer S, Hilger RA, Mühlenberg T, et al. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer. 2014;110(5):1155–1162. doi:10.1038/bjc.2013.82624434430
   PubMed Web of Science ®Google Scholar
• De Marco C, Laudanna C, Rinaldo N, et al. Specific Gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer. PLoS One. 2017;12(6):e0178865. doi:10.1371/journal.pone.017886528662101
   PubMed Web of Science ®Google Scholar
• Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H. Gab2 regulates the migratory behaviors and e-cadherin expression via activation of the pi3k pathway in ovarian cancer cells. Oncogene. 2012;31(20):2512–2520. doi:10.1038/onc.2011.43521996746
   PubMed Web of Science ®Google Scholar
• Wang WJ, Mou K, Wu XF, et al. Grb2-associated binder 2 silencing impairs growth and migration of H1975 cells via modulation of PI3K-Akt signaling. Int J Clin Exp Pathol. 2015;8(9):10575–10584.26617767
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Cid E, Bru S, Yamamoto F. Rare and frequent promoter methylation, respectively, of TSHZ2 and 3 genes that are both downregulated in expression in breast and prostate cancers. PLoS One. 2011;6(3):e17149. doi:10.1371/journal.pone.001714921423795
   PubMed Web of Science ®Google Scholar
• Vié N, Copois V, Bascoul-Mollevi C, et al. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer. 2008;7(1):14. doi:10.1186/1476-4598-7-1418221502
   PubMedGoogle Scholar
• Ross KC, Andrews AJ, Marion CD, Yen TJ, Bhattacharjee V. Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non–small cell lung cancer cells. Mol Cancer Ther. 2017;16(8):1596–1609. doi:10.1158/1535-7163.MCT-16-079828500236
   PubMed Web of Science ®Google Scholar
• Markkanen E, Fischer R, Ledentcova M, Kessler BM, Dianov GL. Cells deficient in base-excision repair reveal cancer hallmarks originating from adjustments to genetic instability. Nucleic Acids Res. 2015;43(7):3667–3679. doi:10.1093/nar/gkv22225800737
   PubMed Web of Science ®Google Scholar
• Labuschagne CF, van Den Broek NJF, Mackay GM, Vousden KH, Maddocks ODK. Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep. 2014;7(4):1248–1258. doi:10.1016/j.celrep.2014.04.04524813884
   PubMed Web of Science ®Google Scholar
• Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012;491(7424):364–373. doi:10.1038/nature1170623151579
   PubMed Web of Science ®Google Scholar
• Luo J. Cancer’s sweet tooth for serine. Breast Cancer Res. 2011;13(6):317. doi:10.1186/bcr293222189202
   PubMed Web of Science ®Google Scholar
• De Marchi T, Timmermans MA, Sieuwerts AM, et al. Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer. Sci Rep. 2017;7(1):2099. doi:10.1038/s41598-017-02296-w28522855
   PubMedGoogle Scholar
• Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43(9):869–874. doi:10.1038/ng.89021804546
   PubMed Web of Science ®Google Scholar
• Possemato R, Marks KM, Shaul YD, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476(7360):346–350. doi:10.1038/nature1035021760589
   PubMed Web of Science ®Google Scholar
• Liu B, Jia Y, Cao Y, et al. Overexpression of phosphoserine aminotransferase 1 (PSAT1) predicts poor prognosis and associates with tumor progression in human esophageal squamous cell carcinoma. Cell Physiol Biochem. 2016;39(1):395–406. doi:10.1159/00044563327372650
   PubMed Web of Science ®Google Scholar